DNLI Denali Therapeutics (DNLI) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001714899
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
175
13F, latest reported quarter
What the filings say about DNLI
Insiders, 180 days
-$435.3K net sold
3 sellers · 60% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$440.4K
4 notices
Denali Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Denali Therapeutics Inc. insiders sold a net $435.3K of stock across 208 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.8% of the 204,538 shares held after it.
- 2 other insiders sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Chin Peter Scott sold about $36.9K of DNLI on Sep 4, 2026; 2 other insiders sold within 30 days and 175 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 53.3% of the 20,301 shares held after it.
- 2 other insiders sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thornberry Nancy sold about $247.3K of DNLI under a 10b5-1 plan on Sep 2, 2026; 2 other insiders sold within 30 days and 175 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.1% of the 19,686 shares held after it.
- 2 other insiders sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thornberry Nancy sold about $14.6K of DNLI under a 10b5-1 plan on Sep 2, 2026; 2 other insiders sold within 30 days and 175 funds added in the latest 13F quarter.Context
- 50 earlier Form 4 trades (code P or S) here by this insider (50 sales), the last on Aug 11, 2026.
- The trade is 1.0% of the 278,995 shares held after it.
- 2 other insiders sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COFO and Secretary Schuth Alexander O. sold about $64.9K of DNLI under a 10b5-1 plan on Sep 1, 2026; 2 other insiders sold within 30 days and 175 funds added in the latest 13F quarter.Context
- 49 earlier Form 4 trades (code P or S) here by this insider (49 sales), the last on Jan 6, 2026.
- The trade is 1.0% of the 281,763 shares held after it.
- 2 other insiders sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COFO and Secretary Schuth Alexander O. sold about $71.6K of DNLI on Aug 11, 2026; 2 other insiders sold within 30 days and 175 funds added in the latest 13F quarter.208 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$435.3K over 180 days
-$435.3K over 90 days
below 54% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
175 funds bought in last quarter
more than 86% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
10.0% of the float short (float per yahoo 2026-10-26) · 7.6 days to cover · settled 2026-09-30
more than 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DNLI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+17.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DNLI: institutional holders (13F)
13F holdings, latest reported quarter
14,026,413 sh
$360.8M
11,960,230 sh
$307.6M
7,049,304 sh
$181.3M
7,012,974 sh
$180.4M
6,477,057 sh
$166.6M
Congress trades in DNLI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DNLI planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Chin Peter Scott
Filed 2026-09-04
$36.9K
NANCY THORNBERRY
Filed 2026-09-02
$266.1K
ALEXANDER SCHUTH
Filed 2026-09-01
$65.8K
Schuth Alexander O.
Filed 2026-08-11
$71.6K
DNLI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$3.4M position · as of 2026-05-31
2.1%
Virtus Biotech Etf
$1.4M position · as of 2026-07-31
1.5%
DANA EPIPHANY SMALL CAP EQUITY FUND
$488.2K position · as of 2026-07-31
1.4%
T. Rowe Price Health Care ETF
$281.9K position · as of 2026-06-30
1.2%
SBH SMALL CAP GROWTH FUND
$3.5M position · as of 2026-06-30
1.0%
Invesco Dorsey Wright Healthcare Momentum ETF
$2.3M position · as of 2026-07-31
1.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
13 registered trials, 9 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
6
Phase 1
3 active
1
Phase 2
1 active
1
Not applicable
0 active
5
Multi-phase
5 active
What changed recently
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfas
2026-09-10 · Recruiting → Active Not Recruiting
PHASE2,PHASE3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Dr. Watts
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.8M
$1.1M
$4.0M
-80%
+25%
2024
$6.6M
$6.1M
$4.0M
-76%
-7%
2023
$7.9M
-$813.5K
$4.2M
-74%
-6%
2022
$9.3M
-$12.1M
$5.2M
-67%
-10%
2021
$12.7M
-$58.2M
$6.6M
-47%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $435.3K sold by insiders over 180 days, 175 funds added last quarter, $440.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
DNLI financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM DNLI
| FY Dec 2025 | n/a |
| FY Dec 2024 | $0 |
| FY Dec 2023 | $330.5M |
| FY Dec 2022 | $108.5M |
| FY Dec 2021 | $48.7M |
| Jun 2026 | $3.6M |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | $0 |
| Mar 2025 | n/a |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM DNLI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -43.9% |
| FY Dec 2022 | -300.6% |
| FY Dec 2021 | -597.2% |
| Jun 2026 | -3,539% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$437.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM DNLI
| FY Dec 2025 | -$422.1M |
| FY Dec 2024 | -$363.6M |
| FY Dec 2023 | -$370.9M |
| FY Dec 2022 | -$262.5M |
| FY Dec 2021 | -$219.9M |
| Jun 2026 | -$97.8M |
| Mar 2026 | -$133.7M |
| Dec 2025 | -$100.1M |
| Sep 2025 | -$105.9M |
| Jun 2025 | -$79.6M |
| Mar 2025 | -$136.5M |
| Dec 2024 | -$88.8M |
| Sep 2024 | -$63.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity DNLI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt DNLI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-54.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity DNLI
| FY Dec 2025 | -45.7% |
| FY Dec 2024 | -37.4% |
| FY Dec 2023 | -14.0% |
| FY Dec 2022 | -32.5% |
| FY Dec 2021 | -27.5% |
| Jun 2026 | -54.9% |
| Mar 2026 | -49.6% |
| Dec 2025 | -45.7% |
| Sep 2025 | -44.4% |
| Jun 2025 | -39.7% |
| Mar 2025 | -35.2% |
| Dec 2024 | -37.4% |
| Sep 2024 | -35.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-44.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DNLI
| FY Dec 2025 | -40.7% |
| FY Dec 2024 | -33.4% |
| FY Dec 2023 | -11.1% |
| FY Dec 2022 | -22.8% |
| FY Dec 2021 | -19.3% |
| Jun 2026 | -44.0% |
| Mar 2026 | -40.0% |
| Dec 2025 | -40.7% |
| Sep 2025 | -39.7% |
| Jun 2025 | -35.9% |
| Mar 2025 | -31.8% |
| Dec 2024 | -33.4% |
| Sep 2024 | -31.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital DNLI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-50.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed DNLI
| FY Dec 2025 | -47.9% |
| FY Dec 2024 | -41.5% |
| FY Dec 2023 | -18.1% |
| FY Dec 2022 | -32.1% |
| FY Dec 2021 | -23.1% |
| Jun 2026 | -50.6% |
| Mar 2026 | -46.9% |
| Dec 2025 | -47.9% |
| Sep 2025 | -47.0% |
| Jun 2025 | -42.6% |
| Mar 2025 | -38.5% |
| Dec 2024 | -41.5% |
| Sep 2024 | -38.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing DNLI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value DNLI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-14.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield DNLI
| FY Dec 2025 | -17.4% |
| FY Dec 2024 | -12.4% |
| FY Dec 2023 | -12.5% |
| FY Dec 2022 | -7.0% |
| FY Dec 2021 | -4.0% |
| Jun 2026 | -10.7% |
| Mar 2026 | -13.8% |
| Dec 2025 | -17.4% |
| Sep 2025 | -19.4% |
| Jun 2025 | -18.1% |
| Mar 2025 | -19.5% |
| Dec 2024 | -12.4% |
| Sep 2024 | -9.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing DNLI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $108.5M |
| Operating income | -$555.3M | -$487.3M | -$196.7M | -$340.7M |
| Net income | -$512.5M | -$422.8M | -$145.2M | -$326.0M |
| EPS (diluted) | -2.97 | -2.57 | -1.06 | -2.60 |
| Operating cash flow | -$412.6M | -$347.7M | -$358.0M | -$244.7M |
| Cash | $205.3M | $175.0M | $127.1M | $218.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
DNLI Stock Sonar score 4/7 axes
Find similar shapesCompareDNLI ranks highest on institutional and government (71st percentile) and profitability (50th), and lowest on insider conviction (27th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
DNLI filings, in plain words
Are Denali Therapeutics insiders buying or selling DNLI?
In the 180 days to 2026-10-28, Denali Therapeutics insiders were net sellers, a net $435.3K across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of DNLI?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $440.4K of stock; the latest, by Chin Peter Scott, was filed 2026-09-04.
Read the full summary
In the 180 days to 2026-10-28, Denali Therapeutics insiders were net sellers of DNLI, a net $435.3K across purchases and sales reported on Form 4 by 3 sellers. 60% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $440.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
